Olaparib (AZD 2281; AstraZeneca, London, UK) is an anti-PARP, which was recently approved by the US Food and Drug Administration and European commission for the treatment of advanced ovarian cancer in patients with BRCA mutations. This evidence concerns the gene PARP1 and ovarian cancer.